Related Experiment Video

Updated: Aug 6, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Multimodal action of antitumor agents on DNA: the ellipticine series

C Auclair1

  • 1Laboratoire de Biochimie-Enzymologie, INSERM U140, CNRS LA 147, Institut Gustave Roussy, Villejuif, France.

Archives of Biochemistry and Biophysics
|November 15, 1987
PubMed

Insights

Ellipticine anticancer drugs target nuclear DNA through various mechanisms, including intercalation and topoisomerase II inhibition. Their antitumor activity is linked to DNA damage, particularly topoisomerase-mediated cleavage, requiring specific structural features.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Medicinal Chemistry

Background:

  • Cytotoxic anticancer agents primarily target nuclear DNA.
  • Ellipticine derivatives exhibit multimodal DNA interactions, including intercalation, covalent binding, and topoisomerase II interference.

Purpose of the Study:

  • To review the relationship between the DNA-targeting mechanisms of ellipticine compounds and their cytotoxic/antitumor activity.
  • To elucidate the role of topoisomerase II inhibition in the efficacy of ellipticine-based anticancer drugs.

Main Methods:

  • Literature review of studies on ellipticine derivatives and their DNA interactions.
  • Analysis of structure-activity relationships concerning DNA binding, oxidative species generation, and topoisomerase II modulation.

Main Results:

  • Ellipticine compounds engage in diverse DNA interactions, contributing to their cytotoxic effects.
  • Topoisomerase II-mediated DNA cleavage is a key mechanism underlying the antitumor activity of ellipticine derivatives.
  • An oxidizable phenolic group or similar structural feature is crucial for topoisomerase II inhibition by these agents.

Conclusions:

  • The antitumor efficacy of ellipticine compounds is strongly associated with their ability to induce topoisomerase II-mediated DNA cleavage.
  • Structural modifications, particularly the presence of an oxidizable phenolic group, are critical for potent topoisomerase II inhibition and anticancer activity.

More Related Videos

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling09:33

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling

Published on: March 20, 2018

Assessment of DNA Double Strand Break Repair Activity Using High-throughput and Quantitative Luminescence-Based Reporter Assays05:01

Assessment of DNA Double Strand Break Repair Activity Using High-throughput and Quantitative Luminescence-Based Reporter Assays

Published on: June 14, 2024

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...